NanoViricides is Expanding its Broad-Spectrum Antiviral Program to Explore Further Antiviral Applications of its COVID Clinical Drug Ingredient
SHELTON, CT / ACCESSWIRE / April 25, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in the development of highly...
IAVI and BARDA Expand Partnership to Advance IAVI’s Filovirus Vaccine Candidates
NEW YORK, NY / ACCESSWIRE / March 2, 2023 / IAVI announced today the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration...